Leukocyte membrane adhesion proteins LFA-1, CR3 and p150,95: A review of functional and regulatory aspects-Reference-Cited by-同舟云学术

Leukocyte membrane adhesion proteins LFA-1, CR3 and p150,95: A review of functional and regulatory aspects

Published:1989-01 Issue:5-6 Volume:140 Page:461-486
ISSN:0923-2494
Container-title:Research in Immunology
language:de
Short-container-title:Research in Immunology

Author:

Kuypers T.W.,Ross D.

Publisher

Elsevier BV

Subject

Immunology

Reference176 articles.

1. Induction of calcium flux and enhancement of cytolytic activity in natural killer cells by cross-linking of the sheep erythrocyte binding protein (CD2) and the Fc-receptor (CD16);Anasetti;J. Immunol.,1987

2. Oligospecificity of the cellular adhesion receptor Mac-1 encopasses an inducible recognition specificity for fibrinogen;Altieri;J. Cell Biol.,1988

3. The saturable high affinity association of factor X to ADP-stimulated monocytes defines a novel function of the Mac-1 receptor;Altieri;J. biol. Chem.,1988

4. Adhesive receptor Mac-1 coordinates the activation of factor X on stimulated cells of monocytic and myeloid differentiation: an alternative initiation of the coagulation protease cascade;Altieri,1988

5. Contributions of the Mac-1 glycoprotein family to adherence-dependent granulocytic functions: structure-function assessments employing subunit-specific monoclonal antibodies;Anderson;J. Immunol.,1986

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efalizumab (Raptiva);Handbook of Therapeutic Antibodies;2014-08-12

2. Leishmania majorinhibits IL-12 in macrophages by signalling through CR3 (CD11b/CD18) and down-regulation of ETS-mediated transcription;Parasite Immunology;2013-11-06

3. Tolerability, pharmacokinetics and pharmacodynamics of CMAB001, an anti-CD11a antibody, in Chinese healthy volunteers and psoriatic patients;Acta Pharmacologica Sinica;2012-07-16

4. Patients with Moderate to Severe Plaque Psoriasis: One Year after the European Medicines Agency Recommendation of Efalizumab Suspension;Dermatology;2011

5. The incidence of arthropathy adverse events in efalizumab-treated patients is low and similar to placebo and does not increase with long-term treatment: pooled analysis of data from Phase III clinical trials of efalizumab;Archives of Dermatological Research;2006-09-21